Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has earned a consensus rating of “Moderate Buy” from the four brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $3.3333.

A number of research firms have recently commented on CGTX. raised shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Friday, March 27th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of Cognition Therapeutics in a research report on Friday, March 27th.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock opened at $1.14 on Friday. The stock’s 50 day moving average is $1.07 and its 200 day moving average is $1.29. Cognition Therapeutics has a one year low of $0.22 and a one year high of $3.83. The firm has a market cap of $102.03 million, a P/E ratio of -4.75 and a beta of 1.81.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Equities analysts anticipate that Cognition Therapeutics will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. grew its stake in Cognition Therapeutics by 34.7% during the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock worth $40,000 after purchasing an additional 7,641 shares during the period. Bryn Mawr Trust Advisors LLC lifted its stake in Cognition Therapeutics by 69.1% in the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after buying an additional 16,129 shares during the period. Jones Financial Companies Lllp acquired a new position in Cognition Therapeutics in the third quarter valued at approximately $25,000. Essex Financial Services Inc. boosted its holdings in shares of Cognition Therapeutics by 100.0% during the 1st quarter. Essex Financial Services Inc. now owns 40,000 shares of the company’s stock worth $30,000 after buying an additional 20,000 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Cognition Therapeutics during the 3rd quarter worth approximately $27,000. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.